Polymorphic Forms of Piperidine-2,6-dione Drug
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione lack stability and bioavailability due to variations in polymorphic forms, which affect solubility, compressibility, and therapeutic efficacy, necessitating the discovery of new polymorphic forms for improved treatment of inflammatory diseases, autoimmune diseases, and cancer.
Innovation Solution
Identification and characterization of polymorphic forms A, B, C, D, E, F, G, and H of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including unsolvated, hemihydrated, and solvated crystalline forms, along with methods for their preparation and use in pharmaceutical compositions for enhanced therapeutic effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical formulations are used, then manufacturing is simplified, but stability and bioavailability are poor due to polymorphic form variations
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions including solvent type (water, ethanol, isopropanol, acetone, toluene, hexane), temperature (room temperature to reflux), and pH levels to obtain different polymorphic forms. Each polymorphic form (A-H) has distinct physical properties such as solubility, melting point, and X-ray diffraction patterns, allowing optimization of stability and bioavailability for specific therapeutic applications.
2Reliability
If a single polymorphic form is used, then formulation complexity is reduced, but solubility and bioavailability may be insufficient for effective treatment
Solution Approach 1:
The patent applies local quality by matching specific polymorphic forms to specific therapeutic requirements. For example, polymorphic forms with higher solubility (determined by solubility studies in various pH buffers) are selected for formulations requiring high bioavailability, while forms with better compressibility are chosen for tablet manufacturing. Each polymorphic form has localized properties optimized for particular aspects of drug performance.
3Manufacturing precision
If polymorphic form variations are not controlled, then manufacturing is easier, but therapeutic efficacy varies due to different physical properties
Solution Approach 1:
The patent applies preliminary action by establishing standardized crystallization protocols and characterization methods before manufacturing. The patent provides predetermined solubility data, melting points, and X-ray diffraction patterns for each polymorphic form, allowing manufacturers to pre-select the appropriate form for their specific therapeutic indication and quality requirements, thereby ensuring consistent therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymorphic forms exhibit improved stability, solubility, and bioavailability, enabling more effective treatment of chronic illnesses such as inflammatory diseases, autoimmune diseases, and cancer, with specific forms suitable for various administration routes and dosage forms.
Implementation Method 1
certain polymorphs of a compound may be more readily soluble in particular solvents
Implementation Method 2
may flow more readily
Implementation Method 3
may compress more easily than others
Data Source
AI summary
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.